← Human Trials & Peer-Reviewed Studies
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study
Plain-language guide to PMID 36087395 (2022): double-blind randomized controlled trial study of Somatostatin and Lanreotide, pancreatitis (after the acute phase).
Key Facts
- PMID
- 36087395
- Journal
- European journal of cancer (Oxford, England : 1990)
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Lepage C et al. (19 authors)
- DOI
- 10.1016/j.ejca.2022.07.033
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Somatostatin and Lanreotide in the context of pancreatitis (after the acute phase).
Following European guidelines, patients with aggressive metastatic or locally advanced, non-resectable, duodeno-pancreatic (DP) neuroendocrine tumours (NETs) should receive systemic combination chemotherapy until progression.
Who Took Part
Patients were randomly assigned in a 1:1 ratio to receive LAN or placebo (PBO), every 28 days, until progression or toxicity.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Somatostatin.
The comparison arm used a placebo, so changes seen with Somatostatin could be set against what happens without it.
The primary end-point was progression-free survival (PFS) at 6 months.
What Was Measured
Topics PubMed links to this paper include Neuroendocrine Tumors, Pancreatic Neoplasms, Peptides, Cyclic and Somatostatin.
Author keywords: Clinical trial, Duodeno-pancreatic, Maintenance, Neuroendocrine tumours and Non-resectable.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Somatostatin and Lanreotide in people with pancreatitis (after the acute phase).
The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (European journal of cancer (Oxford, England : 1990)), a journal based in England.
More context: the Somatostatin compound page and the Lanreotide compound page, Pancreatitis (after the acute phase) research.
Our Notes on the Compounds
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Lanreotide: A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.